registration, and commercialization in multiple countries and regions across the Asia-Pacific, including Southeast Asia, South Korea, Australia, as well as Hong Kong (China), Macau (China), and Taiwan (China). Vicagrel has been granted exclusive rights for clinical development, registration, and commercialization…
On June 9, Zai Lab announced that its ADC novel drug Tisotumab Vedotin has received its first marketing approval in China for the treatment of adult patients with recurrent or metastatic cervical cancer who have progressed during or after chemotherapy.…
Recently, the results of the pivotal ERUPTE Phase II clinical trial, led by Professor Jing Zhicheng from Guangdong Provincial People’s Hospital, were officially published in Med, a Cell Press journal. This study represents a breakthrough in the global development of novel…
On June 8, the NMPA official website showed that Remegen’s Telitacicept (brand name: Tai’ai®) has been approved for two new indications: 1) for the treatment of adult patients with primary immunoglobulin A (IgA) nephropathy at risk of disease progression to significantly…
On June 8, the NMPA official website showed that Teva Pharmaceuticals’ Fremanezumab Injection has been approved for marketing in China. Based on public information and clinical trial progress, the Insight database speculates that the approved indication is for the preventive treatment…
Bexobrutideg (NX-5948), a BTK degrader, is the subject of an exclusive licensing agreement announced on June 8 between Roche and Nurix Therapeutics to co-develop the drug in a deal totaling up to $2.3 billion. The collaboration covers clinical development programs…
On June 8, Zenshine Pharmaceutical issued a press release announcing that a new indication for its Category 1 anti-influenza novel drug Maxeloxaban Tablets (brand name: Jikeshu®) has been approved by the NMPA for the treatment of influenza in adolescents. Previously, in…
On June 8, the CDE official website showed that Hengrui Medicine’s Ruikang Trastuzumab for Injection is proposed to be included in the priority review list for the treatment of adult patients with unresectable or metastatic HER2-low expressing (IHC 1+ or…
Hengrui Medicine, Innovent Biologics, and Haisco Pharmaceutical are among the Chinese biopharma leaders reshaping industry norms. In 2025, the total value of out-licensing deals for Chinese innovative drugs exceeded US$130 billion, reaching a record high. As of now in 2026,…
On June 8, Everest Medicines announced that it has entered into an agreement with箕星药业 (Jixing Pharmaceutical) to acquire the rights to develop, manufacture, and commercialize LNZ100 (1.44% aceclidine, US brand name VIZZ) in Greater China (including mainland China, Hong Kong,…